Table 4.
Generalized Estimating Equations With Logistic Regression Predicting Future Viral Load ≥20 Copies/mL by Tenofovir Diphosphate Concentration for Dried Blood Spot Samples Taken During Viral Suppression
| OR (95% CI) | P | aOR (95% CI) | P | |
|---|---|---|---|---|
| TFV-DP in DBS Concentration at Preceding Visit | ||||
| ≥1850 fmol/punch | Ref | Ref | ||
| 1250-1849 fmol/punch | 1.01 (.38–2.69) | .978 | .86 (.31–2.37) | .772 |
| 700-1249 fmol/punch | 1.12 (.43–2.92) | .817 | 1.04 (.39–2.78) | .939 |
| 350-699 fmol/punch | 3.38 (1.07–10.73) | .038 | 2.47 (.74–8.22) | .140 |
| <350 fmol/punch | 10.67 (2.23–50.97) | .003 | 9.49 (1.92–47.00) | .006 |
| Age, years | .93 (.88–.99) | .0032 | .95 (.89–1.02) | .175 |
| Duration on ART at time of VL, months | 1.00 (.97–1.04) | .798 | .93 (.88–.99) | .031 |
| Duration between DBS and VL specimens, months | 1.22 (1.06–1.41) | .006 | 1.45 (1.16–1.81) | .001 |
N = 255 DBS and VL samples in 81 women.
Abbreviations: aOR, adjusted odds ratio; ART, antiretroviral therapy; CI, confidence interval; DBS, dried blood spot; OR, odds ratio; Ref, reference; TFV-DP, tenofovir diphosphate; VL, viral load.